Načítá se...
Towards better combination regimens of cytarabine and FLT3 inhibitors in acute myeloid leukemia
BACKGROUND: AML patients with FLT3/ITD mutations have poor response to cytarabine-based chemotherapy. FLT3 inhibitors (FLT3i) may resensitize cells to cytarabine (CYT). Improving treatment outcome of this combination may benefit from a mechanistic extrapolation approach from in vitro data. METHODS:...
Uloženo v:
| Vydáno v: | Cancer Chemother Pharmacol |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7539618/ https://ncbi.nlm.nih.gov/pubmed/32748108 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-020-04114-z |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|